The average patient spends five days in the hospital following an MI. Corrie Health takes aim at these patients with a new, immediate approach rather than handing them stacks of written information only at discharge, says Seth Martin, MD, MHS, FACC, Corrie Health's chief medical and scientific officer.

"We're striving to connect with patients as early as possible in their recovery to put the tools for optimal heart attack recovery literally at their fingertips," Martin says. "We want to take complete advantage of the hospital stay to move our patients from informed to engaged to activated in their care."

The approach appears effective and may lower costs, says Francoise Marvel, MD, Corrie Health CEO.

An analysis of the treatment of 80 patients using the Corrie platform shows they are 60 percent less likely to be readmitted to the hospital within 30 days compared with patients not in the program. Only 6 percent of Corrie patients were readmitted in 30 days, and none of those readmissions were related to cardiac issues, she says. The cost of readmission is more than $42,000 per patient, including penalties a hospital may face for exceeding readmission goals.

"The cost of an iPhone or a smartwatch is a drop in the bucket compared to the penalties," Martin says.

In addition, the Centers for Medicare and Medicaid Services has approved a CPT code, which allows for reimbursement of digital monitoring of health, Marvel says. Insurance companies see the benefits of monitoring, with Aetna now providing smartwatches to their insured members to monitor their own health.

"We want to take complete advantage of the hospital stay to move our patients from informed to engaged to activated in their care." — Seth Martin, MD, MHS, FACC

The Corrie Health smart hospital-discharge platform was developed about three years ago at The Johns Hopkins Hospital in Baltimore, MD. As a resident there, Marvel partnered with an engineer and business consultant to develop a prototype, and the team then partnered with Martin, engineers (led by Matthias Lee), Apple professionals and Nucleus Media to create an enhanced and functional version of Corrie.

More than 100 patients now have participated in the program. Some already owned Apple devices while others were provided the Apple equipment for 30 days through the iShare program. iShare promotes health equity by lending devices to patients who are traditionally underserved, Martin states.

The next step for Corrie Health is to commercialize the program and expand it to address other conditions and hospitals. It has been rolled out at Massachusetts General Hospital in Boston, MA, and at Reading Hospital in Reading, PA.

"We are looking to expand our commercial partnerships to accelerate our growth and help more patients," Marvel says. "We want to engage patients and partner with hospitals and insurance companies to improve care. Being part of the Innovation Challenge helped create exposure for Corrie Health and create interest with other hospitals."

<<< Return to Top

CardioFlux, first built in 2016, looks like an MRI scanner, but is less expensive, lighter and does not require the same unique infrastructure, such as liquid helium cooling or a magnetically shielded room. It does not require any room modifications, customized power or ventilation.

The CardioFlux device has two major components. One component is a large chamber that makes it look like an MRI scanner and serves as the magnetic shield. The second component is a device with sensors used to detect and measure the heart's magnetic field. The MCG uses materials, software and processes to create a stable environment needed for the sensitive measurements, Shrivastava says.

Extensive training is not needed to use the Cardioflux MCG. A technician or nurse can perform the 90-second scan, which requires just a few minutes to set up. Because cardiologists and attending physicians have extensive experience at reading ECG data, they can quickly learn to read the MCG data because it stems from the same electrophysiology. Immediately after a scan is completed, the data can be transmitted and processed, and a report can be downloaded electronically.

Magnetocardiography has been studied for 45 years and it has been found to be sensitive for detecting information missed during ECGs or more invasive technologies, such as nuclear stress testing, Shrivastava says. Its drawback was that it was cumbersome, so it was not commonly used. Genetesis founders became familiar with the technology by seeing a parallel when scientists attempted to identify disease currents in isolated heart cells.

"In a clinical trial, we demonstrated CardioFlux's high negative predictive value in patients with low- or intermediate-risk chest pain." — Peeyush Shrivastava

"It was the basic science gold standard for electrophysiology," he says. "In the clinical world, physicians did not have anything as good for clinical decision support. Our team wanted to develop a technology that could translate basic science knowledge to the clinical world. The best method to do that was to perfect magnetocardiography, which has really become a promising solution to bridge this gap."

The team started by designing technology to map irregular heart rhythms and Genetesis was formed in 2013. Their first CardioFlux system was built in 2016. The company expects the device to receive Food and Drug Administration clearance by early next year, and if so, plans to make the CardioFlux available commercially in 2019. The CardioFlux has been through two clinical trials, and later this year a CardioFlux device will be installed at three different institutions.

The CardioFlux could help reduce costs by eliminating inappropriate tests to evaluate chest pain and reducing the length of hospital stays, Shrivastava says, adding that ACC's Innovation Challenge helped Genetesis establish itself in the cardiology world as an innovator.

<<< Return to Top